[Retinopathy, a major cause of blindness in the adult diabetic].
Angioi-Duprez
Karine
K
Service d'ophtalmologie, Hôpital Brabois adultes, CHU de Nancy.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D001766:Blindness / Q000453:epidemiology / Q000209:etiology*; D015984:Causality; D003930:Diabetic Retinopathy / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D018450:Disease Progression; D005451:Fluorescein Angiography; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D053685:Laser Therapy; D008028:Light Coagulation; D008269:Macular Edema / Q000209:etiology; D008301:Maleimides / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D009885:Ophthalmology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D012163:Retinal Detachment / Q000209:etiology; D012720:Severity of Illness Index; D013777:Tetrazoles / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D015351:Vision Screening; D014792:Visual Acuity; D014821:Vitrectomy
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007211:Indoles; D008301:Maleimides; D013777:Tetrazoles; C099154:ruboxistaurin; D011493:Protein Kinase C; D015282:Octreotide; C081643:candesartan